MTD

ACCE-researched
Mettler-Toledo International Inc. Common Stock
Healthcare · Diagnostics & Research · NYSE · United States
$1392.32-1.28%
Market cap $27.9BNext earnings 2026-11-05Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$1392.32+0.0%
confidence-weighted across 4 of 6 models
Now $1392.32
$1392.32
$578.60$1116.43
AvoidSilver66
Price vs fair value
74.0% above
-42.5% to fair value
ACCE score
63
out of 100
Analysts
31% buy
13 covering
P/E
31.3x
forward 26.6x
1-year return
+8.2%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

Reports in 45 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+10.7% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bearish31% buy · 13 covering analysts
● Strong buy 4● Buy 0● Hold 9● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x31.3xhigh 106.5x
ROEbetter than 67% of peers
low -4584%30%high 74%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 1.3%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
DGXQuest Diagnostics Incorporated Common Stock$27.2B26.214.6%0.821.3%-Compare
LHLabcorp Holdings Inc. Common Stock$26.0B26.511.7%0.650.9%-Compare
GHGuardant Health Inc. Common Stock$24.1B--4584.5%-15.420.0%-Compare
ILMNIllumina Inc. Common Stock$36.2B44.632.3%0.730.0%-Compare
IDXXIDEXX Laboratories Inc. Common Stock$40.3B36.074.2%0.530.0%-Compare
WATWaters Corporation Common Stock$41.4B106.51.9%0.730.0%-Compare

Sector report card

Where MTD ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 45 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+7.6%
1 month
-2.3%
3 months
+21.6%
6 months
+15.6%
YTD
-0.1%
1 year
+8.2%

SEC filings

40 filings
September 2026
Sep 1
Form 4Insider transactionPeriod 2026-08-28
August 2026
Aug 31
Form 4Insider transactionPeriod 2026-08-27
Aug 7
Form 4Insider transactionPeriod 2026-08-05
37 more filings + AI summaries on Investor+.INVESTOR